Thermo Fisher Scientific completes Fermentas acquisition

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has completed its previously announced acquisition of Fermentas International Inc. With Fermentas' broad range of high-quality molecular and cellular biology research tools, including reagents, enzymes and kits, Thermo Fisher can offer a complete workflow for genomics research while building on its platform of PCR and qPCR tools and resources.

Fermentas has approximately 500 employees, is headquartered in Burlington, Ontario, and has principal operations in Vilnius, Lithuania. The company had full-year revenues of approximately CAD $57 million in 2009 (approximately USD $55 million). Fermentas will be integrated into Thermo Fisher Scientific's Analytical Technologies Segment.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thermo Fisher Scientific Inc.. (2019, June 18). Thermo Fisher Scientific completes Fermentas acquisition. News-Medical. Retrieved on February 22, 2024 from https://www.news-medical.net/news/20100717/Thermo-Fisher-Scientific-completes-Fermentas-acquisition.aspx.

  • MLA

    Thermo Fisher Scientific Inc.. "Thermo Fisher Scientific completes Fermentas acquisition". News-Medical. 22 February 2024. <https://www.news-medical.net/news/20100717/Thermo-Fisher-Scientific-completes-Fermentas-acquisition.aspx>.

  • Chicago

    Thermo Fisher Scientific Inc.. "Thermo Fisher Scientific completes Fermentas acquisition". News-Medical. https://www.news-medical.net/news/20100717/Thermo-Fisher-Scientific-completes-Fermentas-acquisition.aspx. (accessed February 22, 2024).

  • Harvard

    Thermo Fisher Scientific Inc.. 2019. Thermo Fisher Scientific completes Fermentas acquisition. News-Medical, viewed 22 February 2024, https://www.news-medical.net/news/20100717/Thermo-Fisher-Scientific-completes-Fermentas-acquisition.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
New developments at Evosep to make clinical proteomics 100x more robust and 10x faster